On the morning of October 26, Cully Pharmaceuticals announced on the Hong Kong Stock Exchange that it had submitted a new drug clinical trial application (IND) for ASC39 oral tablets to the US Food and Drug Administration. ASC39 Oral Tablet is an oral small molecule selective insulin receptor agonist used to treat obesity. The company expects to conduct phase I trials in the fourth quarter of 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.